179 related articles for article (PubMed ID: 26344694)
1. Forkhead box K2 modulates epirubicin and paclitaxel sensitivity through FOXO3a in breast cancer.
Nestal de Moraes G; Khongkow P; Gong C; Yao S; Gomes AR; Ji Z; Kandola N; Delbue D; Man EP; Khoo US; Sharrocks AD; Lam EW
Oncogenesis; 2015 Sep; 4(9):e167. PubMed ID: 26344694
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells.
Nestal de Moraes G; Ji Z; Fan LY; Yao S; Zona S; Sharrocks AD; Lam EW
Oncogenesis; 2018 Mar; 7(3):29. PubMed ID: 29540677
[TBL] [Abstract][Full Text] [Related]
3. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.
Khongkow M; Olmos Y; Gong C; Gomes AR; Monteiro LJ; Yagüe E; Cavaco TB; Khongkow P; Man EP; Laohasinnarong S; Koo CY; Harada-Shoji N; Tsang JW; Coombes RC; Schwer B; Khoo US; Lam EW
Carcinogenesis; 2013 Jul; 34(7):1476-86. PubMed ID: 23514751
[TBL] [Abstract][Full Text] [Related]
4. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
[TBL] [Abstract][Full Text] [Related]
5. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
6. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.
Sunters A; Fernández de Mattos S; Stahl M; Brosens JJ; Zoumpoulidou G; Saunders CA; Coffer PJ; Medema RH; Coombes RC; Lam EW
J Biol Chem; 2003 Dec; 278(50):49795-805. PubMed ID: 14527951
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance.
Khongkow P; Karunarathna U; Khongkow M; Gong C; Gomes AR; Yagüe E; Monteiro LJ; Kongsema M; Zona S; Man EP; Tsang JW; Coombes RC; Wu KJ; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2014 Aug; 33(32):4144-55. PubMed ID: 24141789
[TBL] [Abstract][Full Text] [Related]
8. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
[TBL] [Abstract][Full Text] [Related]
9. Forkhead box K2 inhibits the proliferation, migration, and invasion of human glioma cells and predicts a favorable prognosis.
Wang B; Zhang X; Wang W; Zhu Z; Tang F; Wang D; Liu X; Zhuang H; Yan X
Onco Targets Ther; 2018; 11():1067-1075. PubMed ID: 29520156
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt.
Sunters A; Madureira PA; Pomeranz KM; Aubert M; Brosens JJ; Cook SJ; Burgering BM; Coombes RC; Lam EW
Cancer Res; 2006 Jan; 66(1):212-20. PubMed ID: 16397234
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling.
Kim JH; Lee JO; Kim N; Lee HJ; Lee YW; Kim HI; Kim SJ; Park SH; Kim HS
Int J Oncol; 2015 Nov; 47(5):1874-80. PubMed ID: 26397839
[TBL] [Abstract][Full Text] [Related]
12. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
[TBL] [Abstract][Full Text] [Related]
13. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.
Monteiro LJ; Khongkow P; Kongsema M; Morris JR; Man C; Weekes D; Koo CY; Gomes AR; Pinto PH; Varghese V; Kenny LM; Charles Coombes R; Freire R; Medema RH; Lam EW
Oncogene; 2013 Sep; 32(39):4634-45. PubMed ID: 23108394
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival.
Alasiri G; Jiramongkol Y; Trakansuebkul S; Ke HL; Mahmud Z; Intuyod K; Lam EW
Mol Cell Endocrinol; 2020 Sep; 515():110932. PubMed ID: 32615282
[TBL] [Abstract][Full Text] [Related]
15. The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells.
Krol J; Francis RE; Albergaria A; Sunters A; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3169-79. PubMed ID: 18089711
[TBL] [Abstract][Full Text] [Related]
16.
Yu Y; Cao WM; Cheng F; Shi Z; Han L; Yi JL; da Silva EM; Dopeso H; Chen H; Yang J; Wang X; Zhang C; Zhang H
bioRxiv; 2023 May; ():. PubMed ID: 37398114
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of FOXK2 is associated with poor prognosis in patients with gastric cancer.
Liu X; Wei X; Niu W; Wang D; Wang B; Zhuang H
Mol Med Rep; 2018 Nov; 18(5):4356-4364. PubMed ID: 30221666
[TBL] [Abstract][Full Text] [Related]
19. FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.
Liu Y; Ao X; Jia Z; Bai XY; Xu Z; Hu G; Jiang X; Chen M; Wu H
Sci Rep; 2015 Mar; 5():8796. PubMed ID: 25740706
[TBL] [Abstract][Full Text] [Related]
20. FOXK2 transcription factor and its roles in tumorigenesis (Review).
Wang Z; Liu X; Wang Z; Hu Z
Oncol Lett; 2022 Dec; 24(6):461. PubMed ID: 36380871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
